Interferon treatment may trigger primary headaches in multiple sclerosis patients

Multiple Sclerosis

Volumn 12, Issue 4, 2006, Pages 476-480

  La Mantia, Loredana ^a   D'Amico, D ^a   Rigamonti, A ^a   Mascoli, N ^a   Bussone, G ^a   Milanese, C ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Azathioprine; Glatiramer acetate; Interferon 1a; Interferon 1b; International headache society (IHS) criteria; Migraine; Primary headaches; Tension type headache

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG INDUCED HEADACHE; FAMILY HISTORY; FEMALE; FREQUENCY ANALYSIS; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MIGRAINE WITHOUT AURA; MULTIPLE SCLEROSIS; PREVALENCE; TENSION HEADACHE;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AZATHIOPRINE; FEMALE; HEADACHE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; PREVALENCE;

EID: 33746568332     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458506ms1298oa     Document Type: Article

References (28)

1. Nelley LK, Goodin DS, Goodkin DE, Hauser SL. Side effect profile of interferon beta-1b in MS: results of an open trial. Neurology 1996; 46: 552-54.
2. Walther EU, Hohlfeld R. Multiple sclerosis. Side effects of interferon beta therapy and their management. Neurology 1999; 53: 1622-27.
3. Galetta SL, Markowitz C. US FDA-approved disease-modifying treatments for multiple sclerosis. Review of adverse effect profiles. CNS Drugs 2005; 19(3): 239-52.
4. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
5. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85.
6. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
7. PRIMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. PRIMS (prevention of relapses and disability by interferon beta 1a subcutaneously in multiple sclerosis) Study Group. Lancet 1998; 352: 1498-504.
8. The Once Weekly Interferon for MS Study Group (OWIMS). Evidence of interferon β-1a dose response in relapsing-remitting MS. Neurology 1999; 53: 679-86.
9. Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, D'Amico R et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003; 361: 545-52.
10. Brandes JL. Migraine induced by interferon beta therapy for multiple sclerosis. Neurology 2000; 54 (Suppl 3): A422 (Abstract).
11. Pöllmann W, Erasmus L-P, Feneberg W, Then Berg F, Straube A. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS. Neurology 2002; 59: 636-39.
12. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalagia 1988; 8 (Suppl 7): 1-96.
13. D'Amico D, La Mantia L, Rigamonti A, Usai S, Mascoli N, Milanese C et al. Prevalence of primary headaches in people with multiple sclerosis. Cephalalgia 2004; 24: 980-84.
14. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-27.
15. Hadjilambreva G, Mix E, Rolfs A, Müller J. Strauss U. Neuromodulation by a cytokine: interferon beta differentially augments neocortical neuronal activity and excitability. J Neurophysiol 2005; 93: 843-52.
16. Welch KMA. Contemporary concepts of migraine pathogenesis. Neurology 2003; 61 (8 Suppl 4): S2-8.
17. Lang E, Kaltenhauser M, Neundorfer B, Seidler S. Hyperexcitability of the primary somatosensory cortex in migraine - a magnetoencephalographic study. Brain 2004; 127(11): 2459-69.
18. Covelli V, Massari F, Fallacara. C, Munno I, Pellegrino NM, Jirillo E et al. Increased spontaneous release of tumor necrosis factor-alpha/ cachectin in headache patients. A possible correlation with plasma endotoxin and hypothalamic - pituitary - adrenal axis. Int J Neurosci 1991; 61: 53-60.
19. Munno I, Marinaro M, Bassi A, Cassiano MA, Causarano V, Centonze V. Immunological aspects in migraine: increase of IL-10 plasma levels during attack. Headache 2001; 41: 764-67.
20. Rudick RA, Ransohoff RM, Lee SC, Peppler R, Yu M, Mathisen PM et al. In vivo effects of interferon beta 1a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998; 50: 1294-300.
21. Rep MHG, Schrijver HM, van Lopik T, Hintzen RQ, Roos MTL, Adèr HJ et al. Interferon (IFN)-β treatment enhances CD95 and interleukin 10 expression but reduces interferon-y producing T cells in MS patients. J Neuroimmunol 1999; 96: 92-100.
22. Kümpfel T, Then Berg F, Pollmacher T, Holsboer F, Trenkwalder C. Acute effects of interferon beta-1a on plasma cytokine levels in patients with MS. Neurology 2000; 55: 1231-33.
23. Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S et al. Treatment of multiple sclerosis with Copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998; 92:113-21.
24. Thomsen LL, Olesen J. Nitric oxide in primary headaches. Curr Opin Neurol 2001; 14: 315-21.
25. Johnson AW, Land JM, Thompson EJ, Bolanos JP, Clark JB, Heales SJR. Evidence for increased nitric oxide production in multiple sclerosis. J Neurol Neurosurg Psychiatry 1995; 58: 107.
26. Guthikonda P, Baker J, Mattson DH. Interferon-beta-1b (IFN-B) decreases induced nitric oxide (NO) production by a human astrocytoma cell line. J Neuroimmunol 1998; 82: 133-39.
27. Kayhan B, Aharoni R, Arnon R. Glatiramer acetate (Copaxone) regulates nitric oxide and related cytokine secretion in experimental autoimmune encephalomyelitis. Immunol Lett 2003; 88: 185-92.
28. Scher AI, Stewart WF, Lipston RB. Migraine and headache: a meta-analytic approach. In Crombie I ed. Epidemiology of pain. ASP Press, 1999: 159-70.